QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.25    
    


CONFIDENTIAL TREATMENT REQUESTED: CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.  


 AMENDMENT TWO

TO

LIMITED EXCLUSIVE

PATENT, COPYRIGHT AND

TRADEMARK LICENSE AGREEMENT  


 FOR  


 PEREGRINE(TM) DOSE CALCULATION SYSTEM  


 FOR RADIATION TREATMENT PLANNING  


 BETWEEN  


 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA  


 AND  


 NOMOS CORPORATION  


 LLNL CASE NO. TL-1613-99  


 LAWRENCE LIVERMORE NATIONAL LABORATORY

UNIVERSITY OF CALIFORNIA

P.O. BOX 808, L-795, LIVERMORE, CA 94551

INDUSTRIAL PARTNERSHIPS AND COMMERCIALIZATION  


JUNE 2002 






***Confidential material redacted and filed separately with the Commission.





 
 
 

License Agreement—LLNL Case Number TL-1613-99
  For PEREGRINE(TM) DOSE CALCULATION SYSTEM
  For Radiation Treatment Planning
  between NOMOS Corporation and
  The Regents of the
University of California effective July 20, 1999    




        This
Amendment Two to the License Agreement by and between The Regents of the University of California ("THE REGENTS") and NOMOS Corporation ("LICENSEE") will be effective as of the date
of execution of this Amendment by both Parties. This Amendment and the associated License Agreement are subject to overriding obligations to the Federal Government pursuant to the provisions of THE
REGENTS' Contract No. W-7405-ENG-48 with the United States Department of Energy ("DOE") for the operation of the Lawrence Livermore National Laboratory
("LLNL"). 


        This
Amendment Two will modify the field of use, some performance obligations, and royalty fees as reflected in the amended Exhibits B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS) and C
(FEES AND ROYALTIES). All other terms and conditions remain the same. 


        Therefore,
in consideration of the mutual covenants and obligations recited herein, THE REGENTS and LICENSEE hereby amend the License Agreement as follows: 


	1.
	EXHIBIT
B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS) AND EXHIBIT C (FEES AND ROYALTIES) are replaced in their entirety as follows: 


 
 

EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS    
    


NOTICE


        LICENSEE
CONSIDERS INFORMATION IN THIS EXHIBIT B TO BE PROPRIETARY. 


	B.1
	RIGHTS
GRANTED



	B.1.1
	Rights
to Licensed Patents 







Subject
to the limitations set forth in this Agreement, THE REGENTS hereby grants to LICENSEE an exclusive, nontransferable, royalty-bearing license to: 1) make, have made, use, sell, offer for
sale, and import Licensed Products in the Field of Use, and b) practice Licensed Methods in the Field of Use. 



	B.1.2
	Rights
to Licensed Copyrights 





Subject
to the terms and conditions of this Agreement, THE REGENTS grants to LICENSEE an exclusive, nontransferable, royalty-bearing license to duplicate, display, perform, make Derivative Works,
distribute and have distributed, and sell Licensed Products covered by Licensed Copyrights in the Field of Use. 



	B.1.3
	Rights
to Licensed Trademarks 



Subject
to the terms and conditions of this Agreement, THE REGENTS hereby grants LICENSEE an exclusive license to use Licensed Trademarks, in corresponding Territories, as specified in
Exhibit E (LICENSED TRADEMARKS), on Licensed Products or for Licensed Methods in the Field of Use. 



	B.1.4
	"Field
of Use" means planning human and animal cancer therapies based on tumor radiation with photons or electrons that are generated either by a radiation source external to the
patient (teletherapy) or an encapsulated radiation source internal to the patient (brachytherapy). 



1





 




	B.2
	SUBLICENSING
RIGHTS 



THE
REGENTS also grants to LICENSEE the right to issue royalty-bearing sublicenses to third parties in the Field of Use, having rights no greater than those granted to LICENSEE, provided that LICENSEE
has exclusive rights in such Licensed Patents, Licensed Copyrights, and Licensed Trademarks in the Field of Use at the time of sublicensing. LICENSEE may issue sublicenses to Licensed Trademarks only
in conjunction with LICENSEE's sublicensing of Licensed Patents and Licensed Copyrights. 


A
Use Sublicense is considered to be a Licensed Product and not a sublicense as contemplated in this B.2. 



	B.3
	RIGHTS
EXCLUDED 



Rights
that are not specifically granted in this Exhibit B or elsewhere in this Agreement are specifically excluded from the license. In particular, no license, express or implied, is granted
to LICENSEE to Licensed Trademarks outside the corresponding Territory as specified in Exhibit E (LICENSED TRADEMARKS). 



	B.4
	FUTURE
RIGHTS 



Licensable
WFO Subject Inventions and Licensable WFO Computer Software will be added to Exhibit A by amendment. 



	B.5
	PERFORMANCE
OBLIGATIONS



	B.5.1
	LICENSEE
will proceed diligently to develop, file relevant regulatory applications for and attempt to obtain relevant regulatory commercialization approvals with respect to the
manufacturing, marketing, and sale of Licensed Products for all uses in the Field of Use. LICENSEE will file with the U.S. Food and Drug Administration at least one 510k Application or PMA
(Pre-Market Approval) for clearance of Licensed Products for at least teletherapy uses within one (1) year of the Effective Date. 







Notwithstanding
any other term of this Agreement, for the purposes of (a) invoking/complying with the Hatch-Waxman Act (35 U.S.C. Section 156) and any corresponding rules and regulations
of the U.S. Patent & Trademark Office regarding patent term extension, and (b) seeking regulatory approval of LICENSEE's Licensed Products and Licensed Methods, LICENSEE shall act as THE
REGENTS' agent. To the extend deemed necessary by LICENSEE, in good faith, the Parties will cooperate to secure regulatory approval of LICENSEE's Licensed Products and Licensed Methods. 



	B.5.2
	LICENSEE
will release for distribution and offer Sales of Licensed Products by the later date of either October 1, 2000, or within sixty (60) days after the date of
FDA clearance for teletherapy uses of Licensed Products.



	B.5.3
	LICENSEE
will have gross revenues from Sales of Licensed Products or use of Licensed Methods of at least [***] per calendar year, as measured at the close of
LICENSEE'S business on December 31 of the relevant calendar year, commencing with the later of calendar year 2004, or the first full calendar year after a Licensed Product has been released for
distribution and offered for sale in accordance with paragraph B.5.2.



	B.5.4
	LICENSEE
will release for distribution and offer first OEM sale of Licensed Products that interface with radiation treatment planning systems that are manufactured and sold, or
otherwise distributed to third parties, by entities other than LICENSEE by the later date of either October 1, 2001, or one year after initial release for distribution and offer of Sales of
Licensed Products as defined in B.5.2. To the extent that some commercial entities may prefer to sublicense Licensed Patents and Licensed Copyrights rather than to purchase Licensed 



2





 


Products
on an OEM basis, LICENSEE's sublicenses may satisfy this OEM performance obligation. 



	B.5.5
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for brachytherapy by the later date of either [***], or
within sixty (60) days after the date of FDA clearance for brachytherapy uses of Licensed Products.



	B.5.6
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for inverse treatment planning by the later date of either
[***], or within sixty (60) days after the date of FDA clearance for inverse treatment planning uses of Licensed Products.



	B.5.7
	LICENSEE
will release for distribution and offer first sale of Licensed Products in the Field of Use for electron radiotherapy by the later date of either
[***], or within sixty (60) days after the date of FDA clearance for electron radiotherapy uses of Licensed Products.



	B.5.8
	The
sales and other performance requirements specified above may, by mutual written consent of LICENSEE and THE REGENTS, be amended and/or extended at the written request of
LICENSEE to THE REGENTS, based upon legitimate business or technical reasons specified in reasonable detail in such written request. THE REGENTS will not unreasonably withhold its consent to requests
made in accordance with this paragraph.



	B.5.9
	The
first progress report will be due on February 28, 2000. 



 
 

EXHIBIT C—FEES AND ROYALTIES NOTICE    
    



        LICENSEE CONSIDERS INFORMATION IN THIS EXHIBIT C TO BE PROPRIETARY. 


	C.1
	LICENSE
ISSUE FEE



	C.1.1
	As
partial consideration for this Agreement, LICENSEE will pay to THE REGENTS a nonrefundable issue fee of Three Hundred Thousand Dollars ($300,000) (License Issue Fee) as follows:



	C.1.1.1
	Fifty
Thousand Dollars ($50,000.00) to be paid when LICENSEE executes the Agreement.



	C.1.1.2
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than October 1, 1999.



	C.1.1.3
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than November 1, 1999.



	C.1.1.4
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than December 1, 1999.



	C.1.1.5
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than January 1, 2000.



	C.1.1.6
	Fifty
Thousand Dollars ($50,000.00) to be paid no later than February 1, 2000.






	C.1.2
	THE
REGENTS will execute the Agreement after receipt of LICENSEE's executed copies of the Agreement and payment of the first installment of the License Issue Fee specified in
C.1.1.1 above.



	C.1.3
	The
License Issue Fee will not be credited against any other royalty or fee due from LICENSEE to THE REGENTS.



	C.1.4
	In
the event that LICENSEE grants sublicenses, LICENSEE will collect an issue fee equal to or greater than the License Issue Fee. LICENSEE will pay to THE REGENTS fifty percent
(50%) of any issue fee from sublicensing. 





3





 




	C.2.
	EARNED
ROYALTIES 



In
addition to the License Issue Fee, LICENSEE will pay THE REGENTS an earned royalty equal to eight percent (8%) of Net Sales by LICENSEE and any sublicensees. The earned royalty on sales of any
Licensed Product that is sold as part of a larger product system, shall be based on the average Net Sales of that Licensed Product sold separately on a non-OEM basis over the relevant
royalty reporting period. For the purposes of calculating earned royalties, the minimum value of any License Product shall be Fifty Thousand Dollars ($50,000.00) for the first two (2) full
years after the date of initial release for distribution and offer of Sales of Licensed Products as specified in B.5.2. The minimum value shall be Thirty-Five Thousand Dollars ($35,000.00) for the
next two (2) full years, and Twenty-Five Thousand Dollars ($25,000.00) thereafter. 


Payments
of earned royalties will be in accordance with the requirements of Article 4.2 (SUBLICENSING RIGHTS AND OBLIGATIONS), Article 5 (FEES, ROYALTIES AND PAYMENTS) and
Article 7 (PROGRESS AND ROYALTY REPORTS) of this Agreement. 



	C.3
	MINIMUM
ANNUAL ROYALTIES 



LICENSEE
will pay to THE REGENTS a minimum annual royalty according to the requirements of Article 5 (FEES, ROYALTIES AND PAYMENTS) and the schedule below. Earned royalties paid to THE REGENTS
for Net Sales during a calendar year will be accrued and credited against the minimum annual royalty paid for that same calendar year. 



	Calendar Year
 
	 	Minimum Annual Royalty
	 	Due Date In Calendar Year

	2000	 	$35,000	 	February 28
	

2001	
 	

$135,000	
 	

February 28
	

2002	
 	

[***] of cumulative annual revenue* sales up to [***]

 

[***] of cumulative annual revenue sales greater than [***] but less than [***]

 

[***] of cumulative annual revenue sales greater than [***]	
 	

February 28
	

2003	
 	

Same as 2002	
 	

February 28
	

2004	
 	

[***]	
 	

February 28
	

2005 and thereafter for the life of this Agreement	
 	

$400,000.00	
 	

February 28






	*
	As
used herein, the term "cumulative annual revenue" means any revenue generated from sales of the Licensed Products or use of the Licensed Methods, accumulated or realized during the
period January 1 to December 31 of a given year, in this instance, the years 2002, and 2003. 


4





 

        THE
REGENTS and LICENSEE execute this Amendment, in duplicate originals, by their respective officers who are duly authorized on the day and year that is written. 



	
NOMOS CORPORATION	
 	

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
	

 	

 	
 	

LAWRENCE LIVERMORE NATIONAL LABORATORY
	

By:	

/s/  FRED L. MARRONI      
 (Signature)	
 	

By:	

/s/  KARENA MCKINLEY      
 (Signature)
	Name:	Fred L. Marroni
	 	Name:	Karena McKinley

	Title:	VP—Engineering & Development
	 	Title:	Director, IPAC

	

Date signed:  June 3, 2002	
 	

Date signed:  June 4, 2002




5









QuickLinks



EXHIBIT 10.25


License Agreement—LLNL Case Number TL-1613-99 For PEREGRINE(TM) DOSE CALCULATION SYSTEM For Radiation Treatment Planning between NOMOS Corporation and The Regents of the University of California effective
July 20, 1999

EXHIBIT B—RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS

EXHIBIT C—FEES AND ROYALTIES NOTICE